eFFECTOR Therapeutics, Inc.

ACTIVE

142 N Cedros Ave Ste B, 加利福尼亚州圣迭戈县, California, United Stateswww.effector.comPublic14 employees$229.3K

Also known as:

EFTRW

eftr

effector

effector therapeutics

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

55.6%

Phase 1

44.4%

Trial Status Distribution

Active, not recruiting

11.1%

Completed

33.3%

Recruiting

11.1%

Terminated

44.4%

Clinical Trials

Trials sponsored by this organization (9)

Intravenous Zotatifin in Adults With Mild or Moderate COVID-19

Phase 1

Completed

interventional

Jul 202136 participants

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

Phase 2

Active, not recruiting

interventional

Jun 202168 participants

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Phase 1

Recruiting

interventional

Oct 201930 participants

An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer

Phase 2

Terminated

interventional

Nov 201816 participants

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Phase 2

Completed

interventional

Jul 201839 participants

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

Phase 2

Terminated

interventional

Nov 20173 participants

A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer

Phase 2

Completed

interventional

Sep 201756 participants

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

Phase 1

Terminated

interventional

Feb 201728 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations